MDMA THERAPY

Introduction: why this question is relevant now

The question “can I still receive MDMA therapy in Amsterdam after July 1, 2025?” is recurring with increasing frequency. This is understandable: around that date, the situation in practice will have changed, causing providers in Amsterdam and elsewhere to communicate more cautiously about what they can and cannot do. At the same time, there is a lot of confusion: terms such as “MDMA therapy,” “guided session,” “retreat,” and “coaching” are used interchangeably, and online accounts diverge.

In this article, we explain what is often meant in practice by an “MDMA session” after July 1, 2025, which forms of guidance are still discussed, and what this means for safety and harm reduction. We make a clear distinction between (1) scientific research, (2) practical information on harm reduction, and (3) anecdotal evidence. This article is intended as general information and is not individual medical, legal, or therapeutic advice.

What people usually mean by “MDMA therapy”

By “MDMA therapy,” people generally mean a guided session in which MDMA is used to support psychological processes, often related to trauma, anxiety, or persistent patterns. In public debate, reference is frequently made to scientific studies investigating MDMA-assisted therapy, usually within strict protocols involving screening, preparation, guidance during the session, and post-session integration.

It is important to note that, outside of research, “MDMA therapy” is not a clear-cut, protected, or standard term. In practice, it can involve various forms of guidance, ranging from talk therapy with preparation and integration to a guided session in a harm-reduction context. The quality, protocol, and safety agreements can vary significantly.

Those who wish to read up on concepts and context can visit the page about MDMA therapy, where the distinction between research, practice context, and supervision is explained.

After July 1, 2025: what does “we cannot supply the fabric” mean in practice?

The cited forum response states that while supervision will still be possible in Amsterdam as of July 1, 2025, the provider themselves can no longer supply (MDMA) analogues. The core of this is a practical shift: supervision and setting can still be discussed, whereas the supply or provision of substances by supervisors is no longer an issue.

What you, as a reader, should primarily take away from this is this: some providers communicate that they offer guidance only, and that participants are themselves responsible for what they do or do not bring. This changes the dynamic and places extra emphasis on risks that previously lay (partly) with an organization, such as origin, composition, and dosage.

Please note: we cannot verify exactly what has changed “everywhere” or how every provider interprets it. Furthermore, laws, regulations, and enforcement may change. Therefore, do not take an online quote as a definitive legal interpretation, but rather as a signal that practices are shifting.

What is still allowed? Two contexts you need to keep separate.

When discussing “what is still allowed,” it is important to distinguish between two contexts, as they often overlap in conversations:

1) Scientific research
MDMA-assisted therapy is being investigated within scientific studies with strict conditions. In such a setting, there is typically a protocol, screening, monitoring, reporting, and aftercare. Access is usually limited and depends on inclusion criteria, location, and available research groups.

2) Practice in a harm-reduction context
Apart from research, there is also discussion in the Netherlands regarding supervised sessions focusing on safety, preparation, guidance, and integration, without this automatically being “therapy” in the research sense. In that practical context, it is often emphasized that no substances are provided and that the guidance focuses on the process, the setting, and risk reduction. Currently, MDMA sessions can only be discussed within scientific research or in practice via harm reduction.

This distinction is important, because otherwise expectations can easily become misplaced. What is called “MDMA-assisted therapy” in studies is not the same as what someone on the internet calls “MDMA therapy.”.

Why this is especially important for safety

When participants bring the material themselves, part of the risk shifts to topics that cannot be “talked away” with good intentions. Consider: unclear origin, varying strength, possible contamination, and the question of whether it is even what people think it is. This is precisely why harm reduction is such an emphatic part of serious guidance: risks are not glossed over, but made explicit.

A responsible harm-reduction approach typically includes topics such as boundaries, consent, general contraindications, mental preparation, setting, sober guidance, emergency scenarios, and integration. This is not intended as a guarantee that it is “safe,” but as an attempt to reduce known risks.

MDMA, trauma, and why people consider this

Much interest in MDMA stems from the way it is studied in research regarding trauma-related complaints. In general, the literature often describes that MDMA can alter the perception of connection and safety and influence emotional processing. At the same time, this does not work for everyone, nor does an intense experience automatically lead to positive change.

In cases of trauma, factors such as stability, resilience, support in daily life, and the presence of comorbid symptoms play a role. Therefore, serious guidance frameworks usually place a strong emphasis on preparation and integration, rather than just on the session itself. There is also uncertainty: not everyone reacts the same way, and difficult after-effects such as sadness, restlessness, or sleep problems may occur.

Those who wish to read in-depth about this subject can delve deeper via MDMA and trauma.

What you can and cannot expect from guidance outside of research

An important point of nuance: guidance in a harm-reduction context is not automatically medical treatment, and it is not a guarantee of recovery. It can, however, consist of clear agreements, support in formulating intentions, maintaining a safe setting, and debriefing experiences. But the frameworks and responsibilities differ per provider.

Questions that help keep expectations realistic:

• Is there a clear intake? For example, regarding health, medication (in broad outline), psychological stability, and personal goals, without making medical claims.

• What does integration look like? Integration is about translating insights into daily life. This can also mean learning to cope with disappointment, confusion, or emotional aftershocks.

• What safety agreements are in place? Think of down-to-earth guidance, boundaries, privacy, a plan for unexpected situations, and clear communication about what the support worker does and does not do.

• How are risks discussed? A reliable harm reduction style makes risks explicit and promises no outcomes.

Regarding analogues and “legal alternatives”: be extra critical

Other substances are also mentioned in the forum text, such as psilocybin truffles and “LSD analogues” and “ketamine analogues”. Such terms may surface in conversations when people are looking for something that is regulated differently (on paper). Nevertheless, it is wise to remain extra critical in this regard.

Why? Because “(still) legal” is not the same as “safe” or “suitable”. The effects, duration, intensity, and risks vary by substance and by person. Additionally, the legal status of analogues can change, and composition or dosage may be uncertain. Here too, it applies that online statements are not always verifiable, and providers may use different interpretations.

Practical harm-reduction points (general, not personal advice)

Anyone considering a guided session can generally look out for the following harm-reduction principles. These are not guarantees or individual advice, but points of attention that often recur in serious guidance:

• Setting and support: A calm, safe environment and level-headed guidance are often essential to prevent escalation and reduce stress.

• Clear boundaries and consent: Make agreements in advance regarding touch, privacy, communication, and what happens in case of discomfort or panic.

• Preparation and integration: Taking time for intention, expectations, and especially for processing afterwards. Integration can also mean planning extra rest and organizing support.

• Honesty about risks: Including the possibility of a difficult experience, emotional dysregulation, or a disappointing result.

Amsterdam specific: why location is less important than setting

Many people search for “Amsterdam” because the services offered there are visible, and because there is a great deal of international attention for psychedelic and MDMA-related guidance. However, the location itself is less important than the framework: how is the work conducted, what are the boundaries, how transparent are they about what is and isn't allowed, and how is safety concretely ensured?

In addition, “in Amsterdam” can also mean that people come from outside the city. In that case, extra practical questions arise, such as travel afterwards, rest, and preventing overstimulation. A session can be intense, and the day after can feel unpredictable. Planning and aftercare are therefore often at least as relevant as the location.

Conclusion

After July 1, 2025, it appears that in practice it is more frequently communicated that guidance during an MDMA session will still be discussed, but that organizations will not provide MDMA (or analogues). This calls for increased realism regarding what a provider does and does not do, and for extra attention to safety, transparency, and harm reduction. Currently, MDMA sessions can only be discussed within scientific research or in practice through harm reduction, and this is an important difference from the “MDMA therapy” that many people associate with media and studies.

Anyone wishing to explore guided sessions further and discuss which form of guidance might be suitable can register via register MDMA session. Keep your expectations realistic: good guidance can help reduce risks and structure the process, but it is no guarantee of a specific outcome.